Literature DB >> 15015793

Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.

Ute Linz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15015793

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  6 in total

1.  Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.

Authors:  Surasak Phuphanich; Sharyn D Baker; Stuart A Grossman; Kathryn A Carson; Mark R Gilbert; Joy D Fisher; Michael A Carducci
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

2.  Repression of phenylacetic acid transport system in Penicillium chrysogenum Wis 54-1255 by free amino acids and ammonium salts.

Authors:  H Martínez-Blanco; A Reglero; M A Ferrero; J M Fernández-Cañón; J M Luengo
Journal:  J Antibiot (Tokyo)       Date:  1989-09       Impact factor: 2.649

3.  Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.

Authors:  Matthew J Baker; Steven Brem; Stephanie Daniels; Beverly Sherman; Surasak Phuphanich
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

4.  The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species.

Authors:  M O James; R L Smith; R T Williams; M Reidenberg
Journal:  Proc R Soc Lond B Biol Sci       Date:  1972-07-25

5.  Phenylalanine and phenylacetate adversely affect developing mammalian brain neurons.

Authors:  K F Swaiman; S R Wu
Journal:  Neurology       Date:  1984-09       Impact factor: 9.910

6.  Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria.

Authors:  D Samid; Z Ram; W R Hudgins; S Shack; L Liu; S Walbridge; E H Oldfield; C E Myers
Journal:  Cancer Res       Date:  1994-02-15       Impact factor: 12.701
  6 in total
  1 in total

1.  Activity of the yeast Tat2p tryptophan permease is sensitive to the anti-tumor agent 4-phenylbutyrate.

Authors:  Ming Liu; William S A Brusilow; Richard Needleman
Journal:  Curr Genet       Date:  2004-11       Impact factor: 3.886
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.